Evidence map›Paper›PMID 41015566›Full record

ReviewZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2025

[Therapeutic effects of natural products on animal models of chronic obstructive pulmonary disease].

Xinru Fei, Guixian Yang, Junnan Liu, Tong Liu, Wei Gao, Dongkai Zhao

Abstract readReviewEnglish Abstract
In one paragraph

Review in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinru FeiSchool of Rehabilitation Medicine, Changchun University of Chinese Medicine, Changchun 130117. 2754373030@qq.com.
Guixian YangDepartment of Training and Education, Third Affiliated Hospital, Changchun University of Chinese Medicine, Changchun 130117.
Junnan LiuDepartment of Pulmonary Diseases, Third Affiliated Hospital, Changchun University of Chinese Medicine, Changchun 130117, China.
Tong LiuDepartment of Pulmonary Diseases, Third Affiliated Hospital, Changchun University of Chinese Medicine, Changchun 130117, China.
Wei GaoDepartment of Pulmonary Diseases, Third Affiliated Hospital, Changchun University of Chinese Medicine, Changchun 130117, China.
Dongkai ZhaoDepartment of Pulmonary Diseases, Third Affiliated Hospital, Changchun University of Chinese Medicine, Changchun 130117, China. 2499515055@qq.com.

Funding

Project of Science and Technology Development Program of Jilin Province 20200404066YYthe Science and Technology Research Project of Education Department of Jilin Province JJKH20241043KJ
6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) currently lacks effective treatments to halt disease progression, making the search for preventive and therapeutic drugs a pressing issue. Natural products, with their accessibility, affordability, and low toxicity, offer promising avenues. Investigating the pharmacological effects and related signaling mechanisms of active components from natural products on COPD animal models induced by various triggers has become an important focus. In animal models induced by cigarette smoke, cigarette smoke combined with lipopolysaccharide (LPS), air pollution, elastase, bacterial or viral infections, the active compounds of natural products, such as flavonoids, terpenoids, and phenolics, can exert anti-inflammatory, antioxidant, mucus-regulating, and airway remodeling-inhibiting effects through key signaling pathways including nuclear factor-erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1), nuclear factor-kappa B (NF-κB), and mitogen-activated protein kinase (MAPK). These findings not only provide a theoretical basis for the clinical diagnosis and treatment of COPD but also point to new directions for future scientific research.

Indexed as

Biological ProductsPulmonary Disease, Chronic ObstructiveAnimalsAnti-Inflammatory AgentsAntioxidantsDisease Models, AnimalFlavonoidsHeme Oxygenase-1HumansNF-E2-Related Factor 2NF-kappa BPhenolsSignal TransductionSmokeTerpenesAnti-Inflammatory AgentsAntioxidantsBiological ProductsFlavonoidsHeme Oxygenase-1NF-E2-Related Factor 2NF-kappa BPhenolsSmokeTerpenesanimal modelschronic obstructive pulmonary diseasemodeling methodsnatural productstherapeutic effects

Identifiers

PMID41015566
PMCPMC12464926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.